(Source: AbbVie Inc) Mar 30, 2016 NORTH CHICAGO, Ill., March 30, 2016 /PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 25 abstracts have been accepted for presentation at The International Liver Congress™ (ILC) 2016 in Barcelona, Spain,April 13-17, including real-world data that support clinical trial results seen in AbbVie's development program with VIEKIRAX®(ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets). Abstracts presented will further expand scientific knowledge of VIEKIRAX and EXVIERA in genotype 1 (GT1) and genotype 4 (GT4) chronic hepatitis C virus (HCV) infected patients, including those with compensated...
↧